Claims for Patent: 5,834,010

Summary for Patent: 5,834,010

Title:	Triacetin as a penetration enhancer for transdermal delivery of a basic drug
Abstract:	A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of a penetration enhancer consisting essentially of triacetin, and a polymer layer preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.
Inventor(s):	Quan; Danyi (Salt Lake City, UT), Deshpanday; Ninad A. (Salt Lake City, UT), Venkateshwaran; Srinivasan (Salt Lake City, UT), Ebert; Charles D. (Salt Lake City, UT)
Assignee:	Theratech, Inc. (Salt Lake City, UT)
Application Number:	08/775,367
Patent Claims:	1. A method of enhancing the rate of transdermal penetration of a basic drug having a pK.sub.a of about 8.0 or greater comprising applying to a selected application situs a matrix patch comprising (a) a biocompatible polymer layer, wherein said biocompatible polymer is a pressure sensitive adhesive selected from the group consisting of acrylics, vinyl acetates, natural and synthetic rubbers, ethylenevinylacetate copolymers, polysiloxanes, polyacrylates, polyurethanes, plasticized polyether block amide copolymers, plasticized styrene-rubber block copolymers, and mixtures thereof; (b) an effective amount of a percutaneously absorbable basic drug having a pK.sub.a of about 8.0 or greater; and (c) an effective amount of a permeation enhancer consisting essentially of triacetin. 2. The method of claim 1 wherein said basic drug is a member selected from the group consisting of oxybutynin, scopolamine, fluoxetine, epinephrine, morphine, hydromorphone, atropine, cocaine, buprenorphine, chlorpromazine, imipramine, desipramine, methylphenidate, methamphetamine, lidocaine, procaine, pindolol, nadolol, carisoprodol, and acid addition salts thereof. 3. The method of claim 2 wherein said effective amount of permeation enhancer comprises about 0.1% to about 50% by weight of triacetin. 4. The method of claim 3 wherein said basic drug is a member selected from the group consisting of oxybutynin and acid addition salts thereof. 5. The method of claim 4 wherein said effective amount of permeation enhancer comprises about 1% to about 40% by weight of triacetin. 6. The method of claim 5 wherein matrix patch further comprises a member selected from the group consisting of diluents, excipients, emollients, plasticizers, skin irritation reducing agents, carriers, and mixtures thereof. 7. The method of claim 6 wherein said basic drug is oxybutynin. 8. The method of claim 7 wherein said adhesive is an acrylic copolymer. 9. The method of claim 8 wherein the permeation enhancer comprises about 2% to about 20% by weight of triacetin. 10. The method of claim 9 wherein said matrix patch comprises a skin irritation reducing agent, wherein said skin irritation reducing agent is glycerin. 11. The method of claim 3 wherein said polymer layer is laminated to an adhesive. 12. The method of claim 3 wherein said polymer layer is overlaid with an adhesive. 13. A matrix patch for transdermal administration of a basic drug having a pK.sub.a of about 8.0 or greater comprising (a) a biocompatible polymer layer, wherein said biocompatible polymer is a pressure sensitive adhesive selected from the group consisting of acrylics, vinyl acetates, natural and synthetic rubbers, ethylenevinylacetate copolymers, polysiloxanes, polyacrylates, polyurethanes, plasticized polyether block amide copolymers, plasticized styrene-rubber block copolymers, and mixtures thereof; (b) an effective amount of a percutaneously absorbable basic drug having a pK.sub.a of about 8.0 or greater; and (c) an effective amount of a permeation enhancer consisting essentially of triacetin. 14. The matrix patch of claim 13 wherein said basic drug is a member selected from the group consisting of oxybutynin, scopolamine, fluoxetine, epinephrine, morphine, hydromorphone, atropine, cocaine, buprenorphine, chlorpromazine, imipramine, desipramine, methylphenidate, methamphetamine, lidocaine, procaine, pindolol, nadolol, carisoprodol, and acid addition salts thereof. 15. The matrix patch of claim 14 wherein said effective amount of permeation enhancer comprises about 0.1% to about 50% by weight of triacetin. 16. The matrix patch of claim 15 wherein said basic drug is a member selected from the group consisting of oxybutynin and acid addition salts thereof. 17. The matrix patch of claim 16 wherein said effective amount of permeation enhancer comprises about 1% to about 40% by weight of triacetin. 18. The matrix patch of claim 17 wherein matrix patch further comprises a member selected from the group consisting of diluents, excipients, emollients, plasticizers, skin irritation reducing agents, carriers, and mixtures thereof. 19. The matrix patch of claim 18 wherein said basic drug is oxybutynin. 20. The matrix patch of claim 19 wherein said adhesive is an acrylic copolymer. 21. The matrix patch of claim 20 wherein the permeation enhancer comprises about 2% to about 20% by weight of triacetin. 22. The matrix patch of claim 21 wherein said matrix patch comprises a skin irritation reducing agent, wherein said skin irritation reducing agent is glycerin. 23. The matrix patch of claim 15 wherein said polymer layer is laminated to an adhesive. 24. The matrix patch of claim 15 wherein said polymer layer is overlaid with an adhesive.